Poor Sleep
Sanofi India Limited and Cipla Limited have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category.
While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
Kailash IVF, the fertility centre under Kailash Healthcare, has completed asuccessful year of providing advanced,…
SS Innovations International, the maker of India’s first and only home-grown surgical robotic system, SSI…
An Ayurvedic preventive wellness brand - Amma Living – has made its entry into India’s…
In an effort to promote early detection and prevention of deadly cancer among court staffs,…
Nearly 90 per cent of glaucoma cases in India remain undiagnosed, experts warned at a…
The All India Institute of Medical Sciences on Wednesday flagged concern over a spurt in…